EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving early phase oncology clinical trial design: The case for finding the optimal biological dose

Alan Phillips iD, Shalini Mondal

Pharmaceutical Statistics · 2023

DOI: 10.1002/pst.2291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2023. Verfasst von Alan Phillips und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Medicine Research, Faculty of Life Sciences and Medicine, King's College London, London, UK. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Historically early phase oncology drug development programmes have been based on the belief that “more is better”. Furthermore, rule‐based study designs such as the “3 + 3” design are still often used to identify the MTD. Phillips and Clark argue that newer Bayesian model‐assisted designs such as the BOIN design should become the go to designs for statisticians for MTD finding. This short communication goes one stage further and argues that Bayesian model‐assisted designs such as the BOIN12 which balances risk‐benefit should be included as one of the go to designs for early phase oncology trials, depending on the study objectives. Identifying the optimal biological dose for future research for many modern targeted drugs, immunotherapies, cell therapies and vaccine therapies can save significant time and resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansBayes TheoremComputer SimulationDose-Response Relationship, DrugMaximum Tolerated DoseResearch DesignClinical Trials as Topic

Stichwörter der Autor:innen

BOINBOIN12oncology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Centre for Pharmaceutical Medicine Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.

ORCID-Profile: Alan Phillips

Zitieren

APA

Phillips, A., & Mondal, S. (2023). Improving early phase oncology clinical trial design: The case for finding the optimal biological dose. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2291

Vancouver

Phillips A, Mondal S. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose. Pharmaceutical Statistics. 2023. doi:10.1002/pst.2291

BibTeX
@article{Phillips2023,
  author = {Phillips, Alan and Mondal, Shalini},
  title = {Improving early phase oncology clinical trial design: The case for finding the optimal biological dose},
  journal = {Pharmaceutical Statistics},
  year = {2023},
  doi = {10.1002/pst.2291}
}
Kostenlos starten →